Medical journal retracts paper on Amgen's Tavneos drug trial after FDA findings

The New England Journal of Medicine retracted a clinical trial article that helped support approval of Amgen's rare-disease drug, citing altered patient outcome data and instances of researcher unblinding. The retraction raises credibility and governance concerns around the underlying evidence base for the drug and could increase regulatory or legal scrutiny. The news is negative for Amgen sentiment, though the immediate market impact is likely limited to the individual stock rather than the broader market.

Analysis

The New England Journal of Medicine retracted a clinical trial article that helped support approval of Amgen's rare-disease drug, citing altered patient outcome data and instances of researcher unblinding. The retraction raises credibility and governance concerns around the underlying evidence base for the drug and could increase regulatory or legal scrutiny. The news is negative for Amgen sentiment, though the immediate market impact is likely limited to the individual stock rather than the broader market.